Top Innovators in the Proton Therapy Systems Market
- IBA (Ion Beam Applications)
- Varian (now part of Siemens Healthineers)
- Hitachi, Ltd.
- Sumitomo Heavy Industries
- Mevion Medical Systems
- ProNova Solutions
- Mitsubishi Electric / Mitsubishi Heavy Industries
- Optivus Proton Therapy
- ProTom International
- Advanced Oncotherapy (LIGHT system developer)
- Toshiba (historical involvement/components)
- ION Beam Applications / IBA subsidiaries & product lines.
- Provision Healthcare
- Panacea (regional system integrator/center developer)
- Best Medical International / Best Particle Therapy
- ITEL Telecomunicazioni (beamline & control integrator)
- Breitfeld & Schliekert / gantry component suppliers
- Accuray (adjacent radiotherapy tech & partnerships)
- Regional OEMs & Chinese proton system developers
- Specialist service providers
Market Growth
The global proton therapy systems market size began at US$ 1.52 billion in 2024 and is forecast to rise to US$ 1.66 billion by 2025. By the end of 2034, it is expected to surpass US$ 3.72 billion, growing steadily at a CAGR of 9.44%.
What are the Key trends in the Proton Therapy Systems Market in 2024?
Technological Advancements: Innovations such as pencil beam scanning, compact systems, and AI integration are enhancing treatment accuracy while lowering operational costs.
- In May 2024, IHH Healthcare strengthened its leadership in Asian cancer care by officially opening the Mount Elizabeth Proton Therapy Centre in Singapore, expanding access to advanced proton therapy treatments in the region.
New Product Launches: The introduction of advanced proton therapy systems with improved precision and efficiency is boosting market growth by expanding access to cutting-edge cancer treatments.
- In January 2024, OncoRay introduced the world’s first whole-body MRI-guided proton therapy system, beginning scientific operations with a prototype that allows real-time MRI tracking of moving tumors during treatment.
Proton Therapy Systems Market Value Chain Analysis
Regulatory Approval
Proton therapy systems require approval from national regulators like the U.S. FDA or India’s AERB, ensuring safety and effectiveness through design, performance, and clinical evaluations before clinical use.
Clinical Trials
Proton therapy systems are being evaluated in clinical trials at leading cancer centers and through organizations such as the National Cancer Institute. These studies target cancers like prostate, brain, and pediatric tumors to assess whether proton therapy matches or outperforms conventional X-ray treatments.
Patient Support and Services
Patient support in proton therapy encompasses clinical services, including consultations, treatment simulations, and customized therapy plans, along with psychosocial care like child life specialists to assist pediatric patients and their families.
Latest Announcement by Industry Leaders
Researchers from Hochschule Zittau/Görlitz and Helmholtz-Zentrum Dresden–Rossendorf, alongside Valencia scientists, have launched a project to enhance proton therapy treatment verification using the Prompt Gamma Ray Timing (PGT) method. The project develops a simulation model to track proton beam range and adjust doses in real time, accounting for patient movements or tumor changes. Dr. Sonja Schellhammer stated, “By developing a simulation model, we can detect deviations during treatment and create data for AI-based analysis and measurement system optimization,” improving therapy precision and safety.
Recent Developments in the Proton Therapy Systems Market
- In March 2025, Apollo Hospitals partnered with Ion Beam Applications (IBA) to launch the Proteus One Proton Beam Therapy system in India. Equipped with DynamicARC® technology, the system delivers precise, personalized cancer treatments, improving effectiveness and patient outcomes. This collaboration enhances access to advanced proton therapy in India, promoting state-of-the-art cancer care and supporting more targeted and efficient radiation treatment options.
- In January 2024, Israel-based P-Cure began constructing a proton therapy center in China through its local subsidiary, aiming to offer affordable cancer treatment and expand access to advanced proton therapy for Chinese patients.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
